Mankind Pharma inks agreement for two insulin analogues in India

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India.

The partnership marks a step in Mankind Pharma’s strategy to strengthen its presence in diabetes care and broaden its portfolio of injectable therapies. The addition of these products will further enhance Mankind Pharma’s position in the injectable diabetes segment, contributing to a more comprehensive portfolio and reinforcing its commitment to addressing the evolving needs of patients.

The partnership further reinforces the company’s commitment to expanding its diabetes portfolio and bringing a broader range of treatment options to patients in India.

Commenting on the partnership, Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma, said, “China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment.”

The partnership with Chongqing Chenan Biopharmaceutical is also aligned with Mankind Pharma’s broader strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities. China’s developing biopharmaceutical ecosystem presents opportunities for Indian pharmaceutical companies to access differentiated and innovative assets that can complement their existing portfolios.